Prosensa notably higher on the day

Shares of Prosensa (RNA +6.4%) are higher on the session.

Investors may be reacting to Adam Feuerstein's mention of the company in his article regarding the FDA's stance on DMD drugs.

"Chew's letter, suggests some wiggle room for the possibility that FDA would... might... possibly... be willing to review [Sarepta's] eteplirsen based on the existing phase II data," Feuerstein writes, before saying that "the same could be said for [RNA] and GSK's drisapersen, if the companies decide to submit data from the failed Phase 3 study."

From other sites
Comments (1)
  • mitrado
    , contributor
    Comments (2033) | Send Message
    $SRPT should change its stock ticker to $AMRN.2 already. :-P


    This AF guy is incredible... and he does the same constantly: first he gets ultra-bullish on a biotech company (the smaller, the better)... then after months and months of pumping up the stock, he starts to get bearish until he destroys the investments of those who have followed him in the first place.
    7 Jan 2014, 04:57 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs